Suh K S, Lilja H, Kamohara Y, Eguchi S, Arkadopoulos N, Neuman T, Demetriou A A, Rozga J
Department of Surgery, Burns and Allen Research Institute, Los Angeles, California, 90048, USA.
J Surg Res. 1999 Aug;85(2):243-50. doi: 10.1006/jsre.1999.5669.
We earlier described a model of fulminant hepatic failure (FHF) in the rat where partial hepatectomy is combined with induction of right liver lobe necrosis. In FHF rats, lack of regeneration of the residual liver was associated with delayed expression of HGF and HGF receptor c-met and elevated blood HGF and TGF-beta1 levels. We then found that intrasplenic hepatocyte transplantation prolonged survival in FHF rats and triggered hepatocyte proliferation in the native liver. The latter effect was associated with accelerated expression of HGF and c-met mRNA in the liver and lowering of blood HGF and TGF-beta1 levels. In the present study we show that in FHF rats, treatment with a bioartificial liver (BAL) had similar effects.
FHF was induced in inbred Lewis rats and after 4 h, Group 1 rats were subjected to a 4-h whole blood perfusion through the BAL loaded with 3 x 10(8) microcarrier-attached syngeneic hepatocytes, whereas Group 2 control rats were treated with the BAL containing microcarriers only.
Compared to sham-BAL-treated rats, the test rats lived longer (28 +/- 5 vs 17 +/- 2 h; P = 0.0005), had better coagulation parameters, maintained higher body core temperature, and showed decreased plasma TGF-beta1 levels. In addition, their liver remnants were HGF positive and showed increased DNA binding of transcription factors engaged in the modulation of hepatocyte proliferation (e.g., STAT3) and liver-specific gene expression (e.g., HNF1, HNF4, C/EBP).
This study demonstrates that hepatocyte-based extracorporeal support not only can provide metabolic support by increasing the available functional liver mass but also is capable of modifying humoral and molecular mechanisms which are responsible for proliferation and organ-specific functions of residual hepatocytes.
我们之前描述了一种大鼠暴发性肝衰竭(FHF)模型,该模型是将部分肝切除术与右肝叶坏死诱导相结合。在FHF大鼠中,残余肝脏缺乏再生与肝细胞生长因子(HGF)及其受体c-met的表达延迟以及血液中HGF和转化生长因子-β1(TGF-β1)水平升高有关。然后我们发现脾内肝细胞移植可延长FHF大鼠的存活时间,并触发天然肝脏中的肝细胞增殖。后一种效应与肝脏中HGF和c-met mRNA的加速表达以及血液中HGF和TGF-β1水平的降低有关。在本研究中,我们表明,在FHF大鼠中,生物人工肝(BAL)治疗具有类似的效果。
在近交系Lewis大鼠中诱导FHF,4小时后,第1组大鼠通过装有3×10⁸个附着于微载体的同基因肝细胞的BAL进行4小时的全血灌注,而第2组对照大鼠仅用含有微载体的BAL进行治疗。
与接受假BAL治疗的大鼠相比,试验大鼠存活时间更长(28±5小时对17±2小时;P = 0.0005),凝血参数更好,维持更高的体核温度,血浆TGF-β1水平降低。此外,它们的肝脏残余物HGF呈阳性,并且参与调节肝细胞增殖(例如信号转导和转录激活因子3,STAT3)和肝脏特异性基因表达(例如肝细胞核因子1,HNF1;肝细胞核因子4,HNF4;CCAAT/增强子结合蛋白,C/EBP)的转录因子的DNA结合增加。
本研究表明,基于肝细胞的体外支持不仅可以通过增加可用的功能性肝脏质量提供代谢支持,而且还能够改变负责残余肝细胞增殖和器官特异性功能的体液和分子机制。